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During the course of biological aging, there is a gradual accumulation of damaged proteins and a concom-
itant functional decline in the protein degradation system. Protein quality control is normally ensured by the
coordinated actions of molecular chaperones and the protein degradation system that collectively help to
maintain protein homeostasis. The carboxyl terminus of Hsp70-interacting protein (CHIP), a ubiquitin ligase/
cochaperone, participates in protein quality control by targeting a broad range of chaperone substrates for
proteasome degradation via the ubiquitin-proteasome system, demonstrating a broad involvement of CHIP in
maintaining cytoplasmic protein quality control. In the present study, we have investigated the influence that
protein quality control exerts on the aging process by using CHIP/ mice. CHIP deficiency in mice leads to
a markedly reduced life span, along with accelerated age-related pathophysiological phenotypes. These features
were accompanied by indications of accelerated cellular senescence and increased indices of oxidative stress.
In addition, CHIP/ mice exhibit a deregulation of protein quality control, as indicated by elevated levels of
toxic oligomer proteins and a decline in proteasome activity. Taken together, these data reveal that impaired
protein quality control contributes to cellular senescence and implicates CHIP-dependent quality control
mechanisms in the regulation of mammalian longevity in vivo.
Maintaining protein folding homeostasis is essential for op-
timum protein performance and normal cellular function. Mo-
lecular chaperones are the group of proteins that perform this
essential housekeeping task. Molecular chaperones and their
cochaperones ensure the proper folding of nascent proteins,
the refolding of damaged/denatured proteins, and the inhibi-
tion of protein aggregates (7, 18). When proteins are mis-
folded, molecular chaperones target these damaged/misfolded
proteins for degradation, primarily through the ubiquitin-pro-
teasome system (UPS), which comprises the major protein
degradation pathway in eukaryotic cells (17).
The carboxyl terminus of Hsp70-interacting protein (CHIP)
possesses U-box-dependent ubiquitin ligase activity as well as
cochaperone/chaperone activity (1, 37) and plays an essential
role in protein quality control by integrating the molecular
chaperone machinery with the UPS (10). CHIP recognizes,
ubiquitinates, and degrades unfolded chaperone substrates (9,
30, 34). CHIP is also a key modulator of the stress response,
controlling the transcriptional activity of heat shock factor 1
(and thereby regulating the expression of heat shock protein)
(11) as well as ubiquitinating and degrading Hsp70 once the
cellular stress response has abated (35). In addition, we have
shown that mice deficient in CHIP have increased sensitivities
to stress associated with hyperthermia and ischemia/reperfu-
sion injury (11, 48). Collectively, these studies indicate that
CHIP plays a key role in regulating protein folding homeosta-
sis in vivo during proteotoxic stress conditions.
Recently, the dysregulation of protein quality control has
been implicated in the pathogenesis of multiple human degen-
erative diseases (2). Impaired protein quality control is linked
to so-called protein conformational diseases such as Parkin-
son’s disease, amyotrophic lateral sclerosis, Alzheimer’s dis-
ease, and Huntington’s disease, all of which are characterized
by excessive protein aggregation and altered UPS function
(36). Interestingly, CHIP serves a protective function in pro-
tein conformational diseases of the nervous system through its
control of homeostasis of disease-related proteins (13, 32). The
accumulation of damaged proteins and concomitant UPS dys-
function has also been linked to the degenerative processes
associated with biological aging in a variety of systems, includ-
ing human, rat, mouse, and Drosophila (16, 19), although
whether this represents a cause or a consequence of aging has
not yet been clearly established. Collectively, these observa-
tions indicate that the ability of the molecular chaperone sys-
tem and UPS to maintain protein folding homeostasis has a
direct impact on the development of protein conformational
diseases and potentially on biological aging as well.
Although studies using invertebrate organisms, such as Cae-
norhabditis elegans and Drosophila melanogaster, have impli-
cated molecular chaperones in organismal longevity (22, 44), it
is not clear whether the effects of chaperones on aging are due
to the suppression of protein misfolding or to other cellular
functions of chaperones. In any event, there is no direct evi-
dence for the regulation of mammalian longevity by protein
quality control mechanisms. Given the central role of CHIP in
coordinating the various arms of the protein quality control
machinery, mice lacking CHIP provide an excellent model to
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test the consequences of impaired protein quality control on
longevity. Here we show that the loss of CHIP reduces longev-
ity and is associated with an accelerated aging phenotype.
Furthermore, we show that CHIP/ mice accumulate dam-
aged proteins and exhibit a decline in proteasome activity that
may be secondary to the accumulation of misfolded proteins.
Our results clarify the involvement of protein quality control
mechanisms in longevity and demonstrate for the first time
that CHIP, through the regulation of protein quality control at
multiple points, is an essential regulator of mammalian lon-
gevity.
MATERIALS AND METHODS
Animals and pathophysiology. The generation of the CHIP/ mice used in
this study has previously been described (11). Both the CHIP/ and CHIP/
mice were maintained on a mixed genetic background of C57BL/6 and 129SvEv.
The body fat percentile and bone mineral density were measured using dual-
energy X-ray absorptiometry (DEXA) scans and subsequently analyzed with a
Lunar PIXImus densitometer (GE-Lunar Corp., Madison, WI). Kyphosis was
evaluated by measuring the Cobb’s angle on whole-body radiographs of mice of
each genotype (42). For histology, tissues were fixed in a 10% formalin solution
overnight, processed for paraffin embedding, and subsequently sectioned. All
animal husbandry and experiments were approved by the institutional care and
use committee for animal research at the University of North Carolina.
MEF culture and 3T9 assays. Murine embryo fibroblasts (MEF) were gener-
ated from embryonic day 13.5 embryos according to standard protocols and
maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum, penicillin (100 U/ml), streptomycin (100 U/ml), and 2-mercaptoethanol
(50 M). For the 3T9 assay, MEFs were plated at a density of 9  105 cells in
100-mm dishes and replated after cell counts every third day to maintain the
same cell density. Population doublings were determined by the following for-
mula: log2 (number of cells harvested/number of cells seeded) (40).
Measuring SA--Gal activity and lipid oxidation. Senescence-associated -ga-
lactosidase (SA--Gal) activity in MEFs and kidneys was measured by X-Gal
(5-bromo-4-chloro-3-indolyl--D-galactopyranoside) staining using a standard,
previously described protocol (14, 31). Lipid oxidation was measured via the
detection of 8-isoprostane levels in tissue lysates. Preparation of the tissue lysates
and the subsequent assay were performed by using the 8-isoprostane enzyme
immunoassay kit (Cayman Chemical, Ann Arbor, MI) according to the manu-
facturer’s protocol.
Measuring 26S proteasome activity using fluorogenic substrates. The 26S
proteasome activity assay was performed as described previously (28). Briefly,
tissues were lysed in lysis buffer (250 mM sucrose, 50 mM Tris, pH 7.5, 5 mM
MgCl2, 0.5 mM EDTA, and 1 mM dithiothreitol) and nucleic acids were digested
with Benzonase (50 U/ml on ice for 15 min). Ten micrograms of cytosolic protein
was added to the proteasome reaction buffer (50 mM Tris, pH 7.5, 40 mM KCl,
1 mM MgCl2, 1 mM dithiothreitol, 0.5 mM ATP, and 0.05 mg/ml bovine serum
albumin) that contained fluorogenic substrates (Suc-LLVY-AMC; 75 M final
concentration). Fluorescence was measured every 1 or 2 min for 60 to 90 min at
37°C using a Wallace Victor2 spectrofluorometer (the excitation wavelength was
355 nm, and the emission wavelength was 460 nm). To remove nonspecific
substrate hydrolysis, proteins were preincubated with the proteasome inhibitor
epoxomycin (50 M) for 30 min at 37°C and fluorescence units were subtracted
from each measurement.
Dot blot analysis. Soluble proteins from brain tissue were prepared in phos-
phate-buffered saline with protease inhibitor under conditions that avoided pro-
tein denaturation and protein misfolding (24). Twenty micrograms of soluble
protein was loaded onto nitrocellulose membrane and blotted using antioligomer
antibodies obtained either from Biosource (A11) or directly as a generous gift
from Charles G. Glabe, University of California, Irvine, CA. Positive and neg-
ative controls for antioligomer immunoblotting were carried out using recombi-
nant proteins for mutant (R120G) and wild-type -B-crystallin, respectively (38)
(a generous gift from Atsushi Sanbe, National Research Institute for Child
Health and Development, Tokyo, Japan). In cases where the blot was subse-
quently probed for actin, protein samples were boiled to expose epitopes for the
actin antibody before being loaded onto nitrocellulose membrane.
RESULTS
Longevity in mice lacking CHIP. CHIP/ mice were gener-
ated in our laboratory to understand the physiologic conse-
quences of impaired cytoplasmic protein quality control in a
mammalian system (11). CHIP/ mice exhibit partial perinatal
lethality that is thought to reflect impaired adaptation to the stress
of parturition (11). Further observation of these mice indicated
that both male and female CHIP/ mice displayed smaller body
sizes that became more obvious as the mice aged (Fig. 1A). To
FIG. 1. CHIP/ mice have shortened life spans compared to those
of CHIP/ mice. (A) Representative photographs of CHIP/ and
CHIP/ mice in indicated age groups, showing that CHIP/ mice
demonstrated small body sizes and enhanced kyphosis relative to age-
matched CHIP/ mice. (B) Kaplan-Meier survival analyses in a co-
hort (male and female) of CHIP/ (n  82) and CHIP/ (n  128)
mice. CHIP/ mice have significantly shortened life spans compared
with those of CHIP/ mice (log rank test, P  0.0001). (C) Kaplan-
Meier survival analyses in CHIP/ male (n  82), CHIP/ female
(n  84), CHIP/ male (n  58), and CHIP/ female (n  45)
mouse groups. CHIP/ male mice showed reduced longevity com-
pared with that of CHIP/ female mice (log rank test, P  0.0324).
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investigate whether CHIP has an impact on longevity or life span,
CHIP/ and CHIP/ mice were monitored over a 2-year pe-
riod. Kaplan-Meier survival analysis indicated that CHIP/ mice
show significantly reduced longevity compared to CHIP/ mice
(log rank test, P  0.0001) (Fig. 1B). Median survival for
CHIP/ mice was 25 months, whereas for CHIP/ mice it was
10 months, representing a 60% decrease in longevity in the
CHIP/ mice. The longevity of CHIP/ mice, in contrast, was
not different from that of wild-type mice (data not shown). The
effect of CHIP on longevity was markedly influenced by gender
(log rank test, P  0.0324) (Fig. 1C). The median survival time for
CHIP/ female mice was 11.2 months, whereas the survival time
for CHIP/ male was only 7.8 months, representing a 31%
gender-specific decrease in longevity. In contrast, CHIP/ male
and female mice showed no difference in life span (log rank test,
P  0.5167). Exhaustive necropsy analyses failed to identify any
consistent morbid pathology in CHIP/ mice that could account
for the decreased longevity. Overall, these data indicate that the
loss of CHIP results in a significantly shortened life span. In
addition, the increased mortality rate in CHIP/ mice is consid-
erably higher in male mice than in female mice, suggesting that
CHIP has a differential effect on gender-related determinants of
longevity.
Accelerated anatomical aging in CHIP/ mice. To test
whether CHIP/ mice exhibit a premature aging phenotype,
we compared age-related pathophysiological phenotypes in
CHIP/ and CHIP/ mice at both 3 months (young adults)
and 12 months (aged adults) of age. In addition, 24-month-old
CHIP/ mice were included as a normal aging wild-type con-
trol that exceeded the life span of CHIP/ mice. Body weights
were significantly decreased in both 3- and 12-month-old
CHIP/ mice compared to weights in age-matched CHIP/
mice (Table 1). Atrophy (calculated by the ratio of tissue
weight [in milligrams] to body weight [in grams]) was acceler-
ated in skeletal muscles (gastrocnemius and quadriceps), thy-
mus, and testes from CHIP/ mice at 12 months of age
(Table 1), consistent with age-dependent atrophy in these or-
gans (5, 43). In contrast, hearts from CHIP/ mice at 12
months of age were larger than those from CHIP / mice at
the same age (Table 1), indicative of acceleration of aging-
induced cardiac hypertrophy (29). Because reduced fat stores
and dermal atrophy, together with decreased subcutaneous
adipose and dermis layers, are sensitive markers of organismal
aging (23), we performed histological analysis of skin and
quantitative analyses of dermal thickness (Fig. 2A and B). The
dermis was significantly thinner, with loss of subcutaneous fat
layers, in both 3- and 12-month-old CHIP/ mice than in the
age-matched controls. In addition, whole-body fat stores (mea-
sured via a DEXA scan) indicated that CHIP/ mice had
decreased whole-body fat content levels at 12 months of age
compared to those of CHIP/ mice of the same age (Fig. 2C).
Lastly, we monitored age-related skeletal changes in these
mice by measuring bone mineral density using DEXA scans as
well as the degree of kyphosis via the Cobb’s angle on radio-
graphic projection of spin. CHIP/ mice had signs of osteo-
porosis, as indicated by a decrease in bone mineral density
(Fig. 2D), as well as severe kyphosis by 12 months of age
(Fig. 2E and F). Collectively, these observations demon-
strate accelerated organismal aging in CHIP/ mice.
Biochemical markers of aging in CHIP/ mice. To de-
termine whether cellular senescence (8) accompanied the
anatomic changes associated with premature aging in
CHIP/ mice, we examined whether CHIP/ mice display
an increased activity of SA--Gal, a molecular marker for
aging, in vivo and in vitro. Frozen sections of kidneys from
CHIP/ mice had more prominent SA--Gal staining in the
cortex at both 3 and 12 months of age, whereas age-matched
CHIP/ mice had minimal staining for SA--Gal activity
(Fig. 3A). Consistent with prior reports (27), there was strong
positive SA--Gal staining in the 24-month-old CHIP/ mice
that were examined as aged positive controls. Primary MEFs
from early and late passages (passage 3 [P3] and P8, respec-
tively) were also examined for SA--Gal activity (Fig. 3B).
CHIP/ MEFs displayed a two- to threefold increase in SA-
-Gal-positive cells at all passages examined (7.8% versus
15.6% and 20.3% versus 56.1% in P3 and P8 MEFs, respec-
tively) compared to the value for CHIP/ MEFs (Fig. 3C).
We also performed 3T9 proliferation assays as a marker for cel-
lular replicative senescence in CHIP/ and CHIP/ MEFs
(Fig. 3D). Consistent with the increased SA--Gal activity in
CHIP/ MEFs, the rate of proliferation was lower than, and
passages to replicative senescence were reduced compared to,
that of CHIP/ MEFs. As has previously been suggested by
others (12), these data suggest that misfolded proteins can acti-
vate the senescence tumor suppressor mechanism.
Increased free radical production and enhanced oxidative
damage are additional cellular phenomena that are closely
associated with the aging process (4), and correlations between
oxidative stress and chaperone expression have previously
been identified in invertebrate models of aging (49). To deter-
TABLE 1. Ratio of tissue weight to body weight for CHIP/ and CHIP/ mice at different agesa
Tissue type
Tissue weight-to-body weight ratio (mg/g) for indicated age and genotype
3 mo 12 mo
	24 mo, CHIP/
CHIP/ CHIP/ CHIP/ CHIP/
Testis 4.10 
 0.16 3.88 
 0.07 3.49 
 0.06 2.91 
 0.24* 3.00 
 0.20
Thymus 1.08 
 0.02 1.03 
 0.07 0.89 
 0.06 0.65 
 0.02** 0.53 
 0.03
Gastrocnemius 7.10 
 0.71 5.07 
 0.28* 5.52 
 0.83 3.30 
 0.42* 4.37 
 0.14
Quadriceps 7.59 
 0.17 6.02 
 0.22** 6.24 
 0.33 4.63 
 0.30** 5.02 
 0.13
Heart 5.62 
 0.25 6.03 
 0.67 7.20 
 0.69 9.59 
 0.67* 9.65 
 0.54
a Asterisks indicate significant differences between CHIP/ and CHIP/ in the same age group (four to eight per group; *, P  0.05; **, P  0.01 Student’s t test).
Data shown are means 
 standard errors of the means. Body weights were 31.88 
 1.46 (CHIP/) and 22.04 
 1.32* (CHIP/) for 3-month-old mice, 34.25 
 1.39
(CHIP/) and 24.01 
 1.06* (CHIP/) for 12-month-old mice, and 31.71 
 0.79 for CHIP/ mice more than 24 months of age.
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mine whether the deletion of CHIP predisposed mice to im-
paired neutralization of aging-related oxidative species, we
compared the free radical activity in plasma and tissues from
CHIP/ and CHIP/ mice by measuring 8-isoprostane lev-
els as an indicator of lipid oxidation (Table 2). Evidence of
increased oxidative damage was widespread in CHIP/ mice,
with significant increases observed in the livers at 3 months and
in plasma, brains, livers, and lungs at 12 months of age com-
pared to the levels seen for tissues from age-matched CHIP/
mice. There is debate as to whether increased oxidative stress
is a cause or consequence of biological aging, and it should be
noted that the accelerated aging seen in CHIP/ is far more
severe than that seen in animals lacking the enzymes (e.g.,
superoxide dismutase and catalase) for metabolizing oxygen
radicals (4). Nonetheless, our observation of premature oxida-
tive damage provides an additional biochemical marker of
accelerated aging in CHIP/ mice, further supporting the
contention that protein quality control mechanisms mediated
by CHIP are required to retard the onset of aging-related
phenotypes in mammals.
FIG. 2. CHIP/ mice exhibit a premature aging phenotype. (A) Representative histological sections of skin from CHIP/ and CHIP/ mice
at indicated age time points (original magnification, 200). The black bar indicates the dermis layer within the skin section. (B) Quantification of
dermal thickness from dorsal skin in indicated genotypes and age groups (three or four mice per group). (C and D) Quantification of body fat stores
(C) and bone mineral density (D) measured by DEXA scan in indicated genotypes and age groups (four to eight mice per group). (E) Repre-
sentative whole-body radiographs show the degree of kyphosis in CHIP/ and CHIP/ mice in indicated age groups. (F) Quantification of
Cobb’s angle, which represents kyphosis, in indicated genotypes and age groups (three to five per group). Data shown are means 
 standard errors
of the means. Error bars indicate standard deviations. Asterisks indicate statistically significant differences (*, P  0.05; **, P  0.01; ***, P 
0.001 [Student’s t test]).
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Age-dependent defects in protein homeostasis in CHIP/
mice. Previous studies support the idea that CHIP is influential
in protecting against the pathogenesis of neurodegenerative
diseases by controlling the folding and degradation of disease-
related proteins in vivo (13, 32). Therefore, we speculated that
CHIP, as a ubiquitin ligase/cochaperone, could also regulate
protein quality control and the acceleration of biological aging.
To test whether CHIP/ mice exhibit defects in protein qual-
ity control, we assessed the accumulation of damaged proteins
in CHIP/ mice. As an indicator of protein damage and
protein folding defects, we used a recently developed antibody
called antioligomer (A11) that detects soluble aberrantly
folded proteins in the brain (24). Antioligomer antibody can
recognize oligomer proteins (A, polyQ, prion, and insulin) in
protein conformational diseases, including Alzheimer’s dis-
ease, prion disease, and desmin-related cardiomyopathy (24,
28, 38). Since this antibody has been used successfully in the
study of neurodegenerative diseases, we isolated cortical tissue
from CHIP/ and CHIP/ mice and tested for antioligomer
staining via dot blot analysis. Aberrantly folded proteins de-
tected by this antibody were present in brain lysates of
3-month-old CHIP/ mice and were even more abundant in
the brains of 12-month-old CHIP/ mice, but were present at
much lower levels in CHIP/ mice of either age (Fig. 4A),
only accumulating in appreciable levels in wild-type mice after
24 months (data not shown). The specificity of this antibody for
misfolded proteins was confirmed by using R120G -B-crys-
tallin as a positive control (38) (Fig. 4B). Quantitative analysis
indicated that levels of aberrantly folded proteins were three-
fold higher in brains of CHIP/ mice at both 3 and 12 months
FIG. 3. Deficiency of CHIP leads to increased SA--Gal activity and replicative senescence. (A) Photographs of SA--Gal staining in kidneys
from CHIP/ and CHIP/ mice in indicated age groups. SA--Gal-positive staining (blue) in the renal cortex was apparent in kidneys from
CHIP/ mice at 3 and 12 months of age as well as in kidneys from 24-month-old CHIP/ mice. (B) Representative images of SA--Gal staining
in CHIP/ and CHIP/ MEFs at P3 and P8 (original magnification, 200). (C) Quantitative analysis of the percentage of SA--Gal-positive
cells from CHIP/ and CHIP/ MEFs at indicated passages. Data shown are means 
 standard errors of the means. Error bars indicate standard
deviations. P values were determined by Student’s t test. (D) 3T9 proliferation analysis in CHIP/ and CHIP/ primary MEFs from different
passages. Data shown are mean 
 standard deviations. P values were determined by Student’s t test.
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of age than the levels in brains from wild-type mice (Fig. 4C).
These analyses provide an in vivo correlate for the protein
quality control mechanism ascribed to CHIP in in vitro studies
(9, 30). Importantly, the accumulation of misfolded proteins in
CHIP/ mice preceded the manifestations of most of the
aging-related biochemical and anatomic phenotypes in these
mice, which invites the consideration of a causative role for
accumulating levels of toxic misfolded proteins in premature
aging.
Protein aggregates, damaged proteins, and toxic oligomers
are known to have inhibitory effects on proteasome activity (3).
The UPS (along with molecular chaperones) is an essential
component in the maintenance of proper protein quality con-
trol via its removal of damaged proteins. The inhibition of
proteasome activity further enhances cellular injury elicited by
aberrant protein conformations, and the measurement of pro-
teasome activity can serve as a cellular marker for the toxic
effects of misfolded proteins in the setting of impaired protein
quality control. Therefore, we investigated whether CHIP de-
ficiency would alter 26S proteasome activity in tissues from
CHIP/ mice. Skeletal muscle, liver, and lung lysates from
CHIP/ and age-matched controls were analyzed for 26S
proteasome activity by using a fluorogenic substrate. In
3-month-old CHIP/ mice and age-matched CHIP/ mice,
no differences in proteasome activity were evident in any of the
tissues assayed (Fig. 5A). However, skeletal muscle and liver
from CHIP/ mice demonstrated a significant reduction in
proteasome activity by 12 months of age compared to tissues
from age-matched CHIP/ mice (Fig. 5B). Taken together,
these data indicate that CHIP/ mice exhibited an accumu-
lation of damaged proteins and a decrease in proteasome ac-
FIG. 4. Accumulation of misfolded proteins in CHIP/ mice.
(A) Expression of misfolded oligomer proteins in brain tissues ob-
tained from indicated genotypes and age groups, as detected by a dot
blot analysis using antioligomer (A11) antibody. Actin was used as a
loading control. (B) Dot blot analysis showing positive and negative
controls for the antioligomer antibody (see Materials and Methods).
(C) Quantification of oligomer expression in brain tissue from the dot
blot shown in panel A. Expression of oligomer was measured relative
to the oligomer level in brain tissues of 3-month-old CHIP/ mice.
Data shown are means 
 standard errors of the means. Error bars
indicate standard deviations. *, P  0.05 (Student’s t test).
FIG. 5. 26S proteasome activity in CHIP/ mice. Comparison of
chymotrypsin-like activity in indicated tissues from CHIP/ and
CHIP/ mice at 3-month (A) and 12-month (B) age groups (three
mice per group). Chymotrypsin-like activity was measured as described
in Materials and Methods by using a fluorogenic substrate (Suc-
LLVY-AMC) specific for chymotrypsin-like activity. The percentile of
26S proteasome activity was measured relative to the activity in
CHIP/ mice from each age group. Data shown are means 
 stan-
dard errors of the means. Error bars indicate standard deviations. *,
P  0.05 (Student’s t test).
TABLE 2. Oxidative damage in tissues as measured by 8-isoprostane levelsa
Tissue type
Mean 8-isoprostane level (pg/ml) 
 SEM for indicated age and genotype
3 mo 12 mo
	24 mo, CHIP/
CHIP/ CHIP/ CHIP/ CHIP/
Plasma 31.33 
 4.01 32.50 
 3.18 53.20 
 10.05 75.00 
 6.72* 80.20 
 13.82
Brain 1,373.59 
 209.28 1,459.41 
 80.71 1,819.20 
 183.09 2,863.07 
 119.87** 2,015.18 
 188.90
Heart 2,404.50 
 100.50 2,698.00 
 354.27 2,754.40 
 676.62 3,339.67 
 579.18* 3,103.32 
 456.36
Liver 3,287.66 
 806.74 4,664.57 
 444.64** 4,631.00 
 205.97 6,247.53 
 541.58* 2,866.39 
 745.34
Lung 630.38 
 131.51 674.10 
 196.30 954.15 
 226.03 1,563.05 
 141.59* 1,849.89 
 329.65
a Asterisks indicate significant differences of 8-isoprostane levels in CHIP/ tissues compared to CHIP/ tissues of the same age group (*, P  0.05; **, P  0.01
Student’s t test).
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tivity compared to CHIP/ mice, suggesting that CHIP defi-
ciency accelerates the aging process, at least in part, by
disturbing protein quality control and accelerating cellular se-
nescence.
DISCUSSION
The fundamental role of molecular chaperones is to assist in
the folding of newly synthesized polypeptides, to build func-
tionally active proteins, and to prevent protein misfolding and
aggregation (7, 18). The importance of molecular chaperones
is clearly recognized in stress conditions, biological aging, and
conformational diseases that are known to provoke protein
misfolding and aggregation (2). In terms of the biological aging
process, studies of C. elegans and D. melanogaster have sug-
gested that molecular chaperones directly control longevity.
For example, Hsf1 knockdown in C. elegans reduces longevity
and mtHsp70 knockdown promotes a progeria-like phenotype
(22, 26). In addition, numerous heat shock proteins (including
Hsp16, mtHsp70, Hsp27, and Hsp70) have also been shown to
be directly related to life span in C. elegans and D. melanogaster
(44, 47). In mammalian systems, molecular chaperones pre-
serve protein homeostasis during the response to stress and
disease conditions. Studies involving Hsf1/ mice suggest that
Hsf1 is required to protect against demyelination and gliosis
that can occur during aging (21), whereas mutations in molec-
ular chaperone genes, such as Hsf4, sHsp, and -B-crystallin,
are known to associate with age-related conformational dis-
eases, such as cataract formation, desmin-related myopathy,
and distal motor neuropathy (6, 15, 45). Despite the above-
mentioned studies, there is no direct evidence indicating a
correlation between molecular chaperones and mammalian
longevity in vivo. The data presented here demonstrate a com-
prehensive age-associated phenotype in various organs and cell
types of mice deficient in the molecular chaperone CHIP (Fig.
2 and 3; Tables 1 and 2). Accelerated aging phenotypes were
exhibited in CHIP/ mice as early as 3 months of age, and the
shortened life spans were associated with a 60% reduction in
median survival (Fig. 1), suggesting that CHIP deficiency leads
to accelerated aging phenotypes, which result in shortened life
spans. From these results, we have established the first in vivo
evidence that molecular chaperones can directly regulate
mammalian aging and contend that CHIP is an essential reg-
ulator of mammalian longevity.
Protein quality control involves ensuring protein folding ho-
meostasis under normal as well as stressful conditions (17). In
addition to maintaining proper protein folding via the molec-
ular chaperone machinery mentioned above, the protein deg-
radation system (primarily the UPS) assists in protein quality
control by removing damaged, unfolded, and potentially toxic
proteins (3). UPS function has been shown to decrease with
age in studies using rodent models as well as in humans (16,
19). UPS function has also been linked to conformational
diseases that present, in part, as an accumulation of damaged/
misfolded proteins (3, 17, 19). The functional ineffectiveness of
the UPS increases damaged or misfolded proteins, resulting in
an overall impairment in protein quality control in disease
conditions as well as during aging (17). In this study, we ex-
amined protein quality control by measuring the accumulation
of damaged proteins and the decline of UPS function. Our
data suggest that CHIP deficiency disturbs the protein quality
control mechanisms in mice. We saw an increase in toxic oligo-
mer proteins in brain tissue and a decrease in UPS function in
CHIP/ mice compared to wild-type controls (Fig. 4 and 5).
We speculate that without CHIP, there is an overload of dam-
aged proteins, along with impaired proteasome activity. This
results in an imbalance in protein quality control, which in turn
could represent a principal mechanism in the determination of
longevity.
It is clear from other studies using animal models that nu-
merous biological factors (including the redox system, DNA
damage, insulin signaling, and functional defects in stem cells)
are affected by the biological aging process (4, 25, 39). From
our studies, the mechanistic basis for premature aging in
CHIP/ is not clear, and we cannot disregard the possibility
that biological systems other than protein quality control may
be affected by CHIP deficiency. CHIP deficiency seems to
increase oxidative damage, especially in lipid oxidation (Table
2). However, the lack of CHIP did not affect the expression of
FOXOs (forkhead-related transcription factors) or the NAD-
dependent histone deacetylase and homologue of the yeast
(Saccharomyces cerevisiae) sirtuin SIRT (data not shown), both
of which are known to contribute to changes in mammalian
longevity (39). In CHIP/ mice, as in several other mamma-
lian models (14, 20, 27, 31), aging closely correlated with the
expression of biomarkers of cellular senescence, consistent
with a possible causal role of senescence in aging (41). Never-
theless, it remains to be determined whether other age-related
signaling pathways may be involved in the premature aging
phenotype seen in CHIP/ mice. In addition, it will be inter-
esting to test whether caloric restriction and exercise, which are
the known ways to improve maximal life span in mammals (33,
46), can modify the aging phenotype and longevity in CHIP/
mice. The observations in this report indicate that CHIP is
required for longevity and, as such, this study is the first dem-
onstration of a direct connection between molecular chaper-
ones and mammalian longevity in vivo. Indeed, we propose
that protein quality control is one of causal mechanisms that
prevent cellular senescence, aging, and longevity in mamma-
lian systems.
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